• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)

    3/6/26 5:00:00 PM ET
    $EFX
    $NBIX
    Finance: Consumer Services
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EFX alert in real time by email

    TROY, Mich., March 6, 2026 /PRNewswire/ -- Equifax Inc.'s recent report has investors wondering if the company's stock is fairly valued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Equifax (NYSE:EFX) as worthy of further study and has named the company its "Stock to Study" for the May 2026 issue for investors' informational and educational use.

    The fundamental data is eye-opening; investors can view Equifax's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., at: https://ssg.betterinvesting.org/trial/ssgplus/?ticker=EFX.

    A full report on Equifax will appear in the May 2026 issue of BetterInvesting Magazine. 

    The same issue of BetterInvesting Magazine will also include a fundamental review of Neurocrine Bio In. (NASDAQ:NBIX), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective. 

    Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.

    Doron P. Levin, an editor of the magazine, serves as the committee's chairperson.

    Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

    About BetterInvesting:

    BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

    Follow us on LinkedIn, Instagram and Facebook.

    Contact: 877-275-6242

    Cision View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-equifax-inc-nyse-efx-and-neurocrine-bio-in-nasdaq-nbix-302707186.html

    SOURCE NAIC-BetterInvesting

    Get the next $EFX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EFX
    $NBIX

    CompanyDatePrice TargetRatingAnalyst
    Neurocrine Biosciences Inc.
    $NBIX
    2/24/2026$160.00Outperform
    Wolfe Research
    Equifax Inc.
    $EFX
    2/17/2026$250.00Buy
    BofA Securities
    Neurocrine Biosciences Inc.
    $NBIX
    1/8/2026$175.00Overweight → Equal-Weight
    Morgan Stanley
    Neurocrine Biosciences Inc.
    $NBIX
    10/21/2025$175.00Buy
    Citigroup
    Equifax Inc.
    $EFX
    10/13/2025$271.00Outperform
    Oppenheimer
    Equifax Inc.
    $EFX
    10/1/2025Neutral
    Seaport Research Partners
    Neurocrine Biosciences Inc.
    $NBIX
    7/21/2025$163.00Buy
    Truist
    Neurocrine Biosciences Inc.
    $NBIX
    7/10/2025$182.00Buy
    Goldman
    More analyst ratings

    $EFX
    $NBIX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Neurocrine Biosciences Inc.

    SCHEDULE 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

    3/27/26 10:50:36 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Equifax Inc.

    DEFA14A - EQUIFAX INC (0000033185) (Filer)

    3/27/26 7:33:10 AM ET
    $EFX
    Finance: Consumer Services
    Finance

    SEC Form DEF 14A filed by Equifax Inc.

    DEF 14A - EQUIFAX INC (0000033185) (Filer)

    3/27/26 7:31:10 AM ET
    $EFX
    Finance: Consumer Services
    Finance

    $EFX
    $NBIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

    Expert panel establishes structured approach to tardive dyskinesia screening, diagnosis and treatment in long-term care, including use of VMAT2 inhibitorsNew post-hoc KINECT‑PRO™ analysis in adults aged 65 years and older demonstrates clinically meaningful patient-reported improvements in tardive dyskinesia impact with INGREZZA® (valbenazine) capsules, reinforcing expert panel recommendationsSAN DIEGO, March 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first expert consensus recommendations focused on screening, diagnosis and treatment of tardive dyskinesia among older adults in long-term care settings. Developed through a multi

    3/26/26 8:30:00 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Equifax Canada Offering ReadyResponse from Breachlink, a Breach Response Coordination Service to Help Empower and Protect Businesses

    TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- Equifax® Canada, a global data, analytics, and technology company, today announced that it is now offering Equifax customers access to ReadyResponse from Breachlink, a leading provider of data breach preparedness, coordination, and incident management. This comprehensive service helps small and mid-sized businesses (SMBs) prepare for, respond to, and recover from cybersecurity incidents, equipping businesses with the roadmap and connections to effectively respond. ReadyResponse combines essential readiness resources, specialized legal expertise, and discounted rates to a curated network of breach response professionals, helping organizations a

    3/19/26 9:30:00 AM ET
    $EFX
    Finance: Consumer Services
    Finance

    Equifax Releases 2025 Security Annual Report

    Sixth Annual Report Highlights AI-Accelerated Defenses, Security-Driven Business Innovation, and Continued Industry CollaborationATLANTA, March 18, 2026 /PRNewswire/ -- Equifax® (NYSE:EFX) today released its 2025 Security Annual Report, detailing a year of relentless optimization as the company leverages EFX.AI to power the future of the organization. The sixth annual report outlines how Equifax is navigating the intersection of AI and cybersecurity from three distinct angles: deploying AI to streamline its own defenses, building the architectural guardrails to secure the business's use of generative AI tools, and recalibrating its posture to mitigate adversarial AI threats.

    3/18/26 7:45:00 AM ET
    $EFX
    Finance: Consumer Services
    Finance

    $EFX
    $NBIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Neurocrine Biosciences with a new price target

    Wolfe Research initiated coverage of Neurocrine Biosciences with a rating of Outperform and set a new price target of $160.00

    2/24/26 7:55:00 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities resumed coverage on Equifax with a new price target

    BofA Securities resumed coverage of Equifax with a rating of Buy and set a new price target of $250.00

    2/17/26 7:37:46 AM ET
    $EFX
    Finance: Consumer Services
    Finance

    Neurocrine Biosciences downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Neurocrine Biosciences from Overweight to Equal-Weight and set a new price target of $175.00

    1/8/26 8:41:09 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EFX
    $NBIX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 13, 2024 - FDA Approves New Treatment for Congenital Adrenal Hyperplasia

    For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con

    12/13/24 5:54:17 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EFX
    $NBIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Product Officer Mao Cecilia bought $464,928 worth of shares (2,400 units at $193.72), increasing direct ownership by 29% to 10,623 units (SEC Form 4)

    4 - EQUIFAX INC (0000033185) (Issuer)

    2/19/26 4:22:27 PM ET
    $EFX
    Finance: Consumer Services
    Finance

    Fichuk Karen L bought $99,090 worth of shares (415 units at $238.77), increasing direct ownership by 14% to 3,305 units (SEC Form 4)

    4 - EQUIFAX INC (0000033185) (Issuer)

    5/10/24 4:24:39 PM ET
    $EFX
    Finance: Consumer Services
    Finance

    Smith Melissa D bought $151,971 worth of shares (914 units at $166.27) (SEC Form 4)

    4 - EQUIFAX INC (0000033185) (Issuer)

    10/30/23 4:39:31 PM ET
    $EFX
    Finance: Consumer Services
    Finance

    $EFX
    $NBIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Pres USIS Smith David John was granted 22,958 shares (SEC Form 4)

    4 - EQUIFAX INC (0000033185) (Issuer)

    3/17/26 9:21:38 PM ET
    $EFX
    Finance: Consumer Services
    Finance

    SEC Form 3 filed by new insider Smith David John

    3 - EQUIFAX INC (0000033185) (Issuer)

    3/17/26 9:19:36 PM ET
    $EFX
    Finance: Consumer Services
    Finance

    New insider Ratz Andrew claimed ownership of 1,018 shares (SEC Form 3)

    3 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

    3/17/26 5:56:51 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EFX
    $NBIX
    Leadership Updates

    Live Leadership Updates

    View All

    Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer

    SAN DIEGO, March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his new role, Dr. Ratz will lead the company's global technical development, manufacturing, and supply chain functions, supporting Neurocrine's expansion beyond small molecules into biologics and device-based therapies. Dr. Ratz – who joined Neurocrine in January 2025 as Senior Vice President of Drug Development, Delivery and Device – previously spent nearly 30 year

    3/17/26 4:05:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Equifax Announces Participation in December Investor Conferences

    ATLANTA, Dec. 1, 2025 /PRNewswire/ -- Equifax® (NYSE:EFX) will participate in two upcoming investor conferences in December. Mark W. Begor, Chief Executive Officer, and John Gamble, Chief Financial Officer, will participate in the Goldman Sachs U.S. Financial Services Conference in New York on Tuesday, December 9, 2025, including participation in a Fireside Chat at 10:00 a.m., Eastern Time. The company invites investors to join a live webcast of this Fireside Chat event at: https://investor.equifax.com/news-events/ir-calendar. A replay of this Fireside Chat will be available w

    12/1/25 4:20:00 PM ET
    $EFX
    Finance: Consumer Services
    Finance

    Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise

    SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neuropsychiatry franchise. Sibley, a proven leader with more than 20 years of commercial experience in the biopharmaceutical industry, will be responsible for developing and executing the sales and marketing strategy for Neurocrine's neuropsychiatry products, including the INGREZZA® franchise. "Mike is an accomplished leader with a strong record of leading high-performing sales and market

    10/6/25 4:05:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EFX
    $NBIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Equifax Inc.

    SC 13G/A - EQUIFAX INC (0000033185) (Subject)

    11/13/24 10:22:19 AM ET
    $EFX
    Finance: Consumer Services
    Finance

    SEC Form SC 13G filed by Neurocrine Biosciences Inc.

    SC 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

    10/17/24 9:54:01 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Equifax Inc. (Amendment)

    SC 13G/A - EQUIFAX INC (0000033185) (Subject)

    2/16/24 4:57:01 PM ET
    $EFX
    Finance: Consumer Services
    Finance

    $EFX
    $NBIX
    Financials

    Live finance-specific insights

    View All

    Equifax Board of Directors Authorizes 12% Dividend Increase

    ATLANTA, Feb. 25, 2026 /PRNewswire/ -- Equifax® (NYSE:EFX) today announced that the Equifax Board of Directors approved a 12% increase in the Company's quarterly cash dividend for the first quarter of 2026. The new quarterly cash dividend is $0.56 per share, subject to future declaration by the Company's Board of Directors. For the first quarter of 2026, the cash dividend of $0.56 per share is payable on March 17, 2026 to shareholders of record as of the close of business on March 9, 2026. Equifax has paid cash dividends for more than 100 consecutive years. ABOUT EQUIFAX INC.At

    2/25/26 4:15:00 PM ET
    $EFX
    Finance: Consumer Services
    Finance

    Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026

    Total Fourth-Quarter and Full-Year 2025 Net Product Sales of $798.3 Million and $2.83 Billion, Representing Year-Over-Year Growth of 29% and 22%, Respectively INGREZZA® (valbenazine) Full Year 2026 Net Product Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the fourth quarter ended December 31, 2025. "Our 2025 performance reflects the strength and durability of our commercial business and meaningful progress we are making transforming Neurocrine into a broader, m

    2/11/26 4:01:00 PM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Equifax Delivers Fourth Quarter 2025 Revenue Growth of 9% Despite Weaker U.S. Hiring and Mortgage Markets

    ATLANTA, Feb. 4, 2026 /PRNewswire/ -- Equifax® (NYSE:EFX) today announced financial results for the quarter and full year ended December 31, 2025. Fourth quarter 2025 revenue of $1.551 billion up 9% and $30 million above the midpoint of guidance, despite headwinds from U.S. Hiring and Mortgage markets.Fourth quarter U.S. Mortgage revenue up a very strong 20% despite decline in underlying Mortgage market.Workforce Solutions fourth quarter revenue up 9%. Verification Services revenue up 10% led by strong low double digit Government growth, with Diversified Markets (previously re

    2/4/26 6:30:00 AM ET
    $EFX
    Finance: Consumer Services
    Finance